Our Parent Company
Established forty years ago, Wockhardt has evolved into
one of India's top five research-based pharmaceutical companies
and is amongst the top seventy-five in the world. The group now
employs over 3,500 people globally.
Wockhardt's insight into evolving global markets has resulted
in a dramatic increase in international business.
Shaping the Future
- A combination
of cutting edge facilities and innovative process development
has resulted in a world-class pharmaceutical
- The Wockhardt facility supports a multidisciplinary research
programme involved in biotechnology, super-generics and new chemical
entities. Key research areas include bio-generics, antibacterials
and nutrition. Wockhardt is the first company outside of the
USA and Europe to manufacture recombinant insulin and the launch
of hepatitis B vaccine was the most successful in Indian history.
- Investment in Research & Development has
reached $43million in the last 5 years alone. Wockhardt’s
policy is to maintain an annual R&D spend approaching 8%
of sales, a figure on par with the world’s elite pharmaceutical
ambition is to refine and develop a global supply chain competence,
a truly integrated service.
To find out more about Wockhardt, please visit www.wockhardt.com. Please note: The information available at this address is aimed at Wockhardt customers in India.